NEW YORK, June 17, 2016 /PRNewswire/ -- CBL & Associates
Properties, Inc. (CBL)
Lifshitz & Miller announces investigation
into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016,
the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to
banks when applying for financial arrangements.
For more information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Eagle Pharmaceuticals, Inc. (EGRX)
Lifshitz & Miller announces
investigation on behalf of EGRX investors. Specifically, on March 18, 2016, EGRX announced
receipt of a CRL from the FDA, regarding Kangio, disapproving the drug application in its current form and requested additional
information regarding the substance used in Kangio.
For more information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
HCP, Inc. (HCP)
Lifshitz & Miller announces
investigation on behalf of HCP investors. Specifically, on February 9, 2016, HCP disclosed
that its equity stake in ManorCare had been written down to zero, and that it had taken an $836
million non-cash impairment on its ManorCare lease assets and placed all of its ManorCare real estate assets on a "Watch
List."
For more information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Immunomedics, Inc. (IMMU)
Lifshitz & Miller announces investigation
into possible breaches of fiduciary duties by Immunomedics board. Specifically, the investigation relates to whether
Immunomedics misrepresented to ASCO that its abstract for IMMU-132 contained only
updated and previously undisclosed data in violation of ASCO's policy.
For more information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Infinity Pharmaceuticals Inc. (INFI)
Lifshitz & Miller announces investigation
into possible breaches of fiduciary duties by the INFI board. Specifically, on June 14, 2016, INFI
announced a restructuring that would reduce its workforce by 21% in the wake of disappointing drug-study results.
For more information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Neovasc, Inc. (NVCN)
Lifshitz & Miller announces investigation
on behalf of Neovasc investors. Specifically, the investigation will focus on multiple media reports that claim a
Massachusetts federal jury awarded a $70 million verdict to
Neovasc's rival, CardiAQ Valve Technologies Inc. ("CardiAQ"), finding that Neovasc had stolen trade secrets from CardiAQ.
For more information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
Unilife Corporation (UNIS)
Lifshitz & Miller announces investigation
into possible breaches of fiduciary duties by UNIS board. Specifically, the investigation relates to whether Unilife's
former CEO and its former Chairman had violated Company policies and broken laws and regulations; and Unilife lacked sufficient
accounting and financial reporting internal controls.
For more information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.
ATTORNEY ADVERTISING. © 2016 Lifshitz & Miller. The law firm responsible for this advertisement is
Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel:
(516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@jlclasslaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifshitz--miller-law-firm-announces-investigation-of-cbl--associates-properties-inc-eagle-pharmaceuticals-inc-hcp-inc-immunomedics-inc-infinity-pharmaceuticals-inc-neovasc-inc-and-unilife-corporation-300286669.html
SOURCE Lifshitz & Miller Law Firm